At 24 weeks, retatrutide at doses of 8 mg and 12 mg resulted in a mean relative liver fat reduction of -81.4% and -82.4% respectively. These reductions further increased at 48 weeks, with the higher-dosage groups reporting changes of -81.7% and -86.0% compared to a 0.3% increase in the placebo group.